Y-mAbs Therapeutics, Inc.
YMAB
$7.08
$0.233.36%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 20.45M | 20.75M | 20.25M | 31.45M | 12.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.45M | 20.75M | 20.25M | 31.45M | 12.54M |
| Cost of Revenue | 2.65M | 4.65M | 2.08M | 2.02M | 2.48M |
| Gross Profit | 17.81M | 16.10M | 18.17M | 29.43M | 10.06M |
| SG&A Expenses | 10.36M | 11.43M | 11.40M | 385.00K | 14.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.20M | 27.97M | 23.27M | 21.11M | 38.55M |
| Operating Income | -7.75M | -7.22M | -3.02M | 10.34M | -26.02M |
| Income Before Tax | -7.56M | -6.12M | -6.39M | 1.16M | -27.53M |
| Income Tax Expenses | 187.00K | 179.00K | -- | -- | -- |
| Earnings from Continuing Operations | -7.75M | -6.30M | -6.39M | 1.16M | -27.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.75M | -6.30M | -6.39M | 1.16M | -27.53M |
| EBIT | -7.75M | -7.22M | -3.02M | 10.34M | -26.02M |
| EBITDA | -7.58M | -7.00M | -2.84M | 10.57M | -25.79M |
| EPS Basic | -0.18 | -0.14 | -0.15 | 0.03 | -0.63 |
| Normalized Basic EPS | -0.11 | -0.09 | -0.03 | 0.20 | -0.39 |
| EPS Diluted | -0.18 | -0.14 | -0.15 | 0.02 | -0.63 |
| Normalized Diluted EPS | -0.11 | -0.09 | -0.03 | 0.20 | -0.39 |
| Average Basic Shares Outstanding | 43.62M | 43.66M | 43.67M | 43.67M | 43.72M |
| Average Diluted Shares Outstanding | 43.62M | 43.66M | 43.67M | 44.69M | 43.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
